A blood-borne virus causes hepatitis C. The epidemic has a strong global influence on the health, epidemiology, and economy. In 60 percent to 80 percent of cases hepatitis C virus (HCV) infections can become chronic, and can be serious, such as liver cirrhosis and primary hepatitis carcinoma. In Germany, it is estimated that there are about 400,000 to 500,000 people who are chronically infected. Since 1990, compulsory blood and plasma donation monitoring has significantly decreased and is extremely low, the risk of viral transmission through blood products. However, the injecting of opioid consumers is a significant risk group. In recent years, opioid treatment efficacy has dramatically increased for chronic infection of the hepatitis C virus. In 50% to 75% of patients according to HCV genotype, continuous viral clearance is achieved. A large percentage of the global population is estimated to have a chronic virus infection. The virus has major heterogeneity, which interferes directly with the management of diseases. Therapy reaction depends on the genotype and subtype of HCV. Continuous variant generation (quassis) helps the virus to avoid antiviral regulation. In the past, the only treatment choice of the condition was a mixture of ribavirin and interferon therapy. Several alternative medical options are now being established and are available to a substantial portion of the population affected. Moreover, the hunt for novel anti-HCV substances begins, predicting potential therapeutic changes. The mutation ability of the virus and other factors affecting therapeutic outcomes should be considered by researchers.